查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1605724

安德森 Tawil 综合征治疗市场，按治疗类型、按药物类别、按给药途径、最终用户、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Andersen Tawil Syndrome Treatment Market, By Treatment Type, By Drug Class, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 392 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023 年，Andersen Tawil 症候群治疗市场规模为 17.6523 亿美元，2024 年至 2032 年复合年增长率为 7.2%。

安德森塔维尔症候群治疗市场-市场动态

基因疗法的进步和远距医疗的扩展推动了安德森-塔维尔症候群治疗市场的成长

基因疗法的进步，加上远距医疗服务的扩展，正在显着推动安德森-塔维尔症候群治疗市场的发展。在《美国远距医疗现代化法案》等措施的支持下，远距医疗平台的实施增加了偏远地区患者获得专业照护的机会。美国国立卫生研究院 (NIH) 等机构正在资助研究开发标靶疗法，其中有超过 50 项活跃的研究重点关注遗传性疾病，包括安德森-塔维尔症候群。此外，远距医疗日益融入医疗保健系统，使近 60% 的罕见疾病患者无需出差即可咨询专家，从而改善了管理和遵守治疗方案。

Andersen Tawil 综合症治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 7.2% 左右的复合年增长率成长

根据治疗类型细分，预计药物将在 2023 年显示最大的市场份额

根据药物类别细分，碳酸酐酶抑制剂是2023年的主导类型

依给药途径细分，2023年口服给药为主导类型

按地区划分，北美是 2023 年的主要收入来源

安德森塔维尔症候群治疗市场-細項分析：

全球安徒生泰维尔症候群治疗市场根据治疗类型、药物类别、给药途径、最终用户和地区进行细分。

根据治疗类型，市场分为两类：药物治疗和物理治疗。药物在安德森-塔维尔症候群治疗市场中具有最高优先级，因为它直接解决心律不整和週期性麻痹等症状。接下来是物理治疗，在提高肌肉力量和活动能力以实现长期管理和患者生活品质方面发挥着至关重要的作用。

根据药物类别，市场分为三类：碳酸酐酶抑制剂、β-受体阻断剂和钾补充剂。碳酸酐酶抑制剂因其在控制週期性麻痹发作方面的有效性而被优先考虑。随后是β受体阻断剂，可治疗安德森-塔维尔症候群常见的心律不整。钾补充剂处于第三位，对于纠正低血钾以及稳定患者的肌肉和心臟功能至关重要。

安德森塔维尔症候群治疗市场 - 地理洞察

在强大的医疗基础设施和罕见疾病研究资金增加的推动下，北美在安德森-塔维尔症候群治疗市场占据主导地位。该地区受益于美国国立卫生研究院 (NIH) 支持的罕见疾病临床研究网络 (RDCRN) 等倡议，该网络已促进了 70 多项关于遗传性疾病的合作研究。 2023 年，美国一家领先的製药公司与一家生技公司建立了重要合作伙伴关係，开发新型钾通道调节剂，旨在解决与安德森-塔维尔症候群相关的周期性麻痹。欧洲紧随其后，欧洲药品管理局 (EMA) 授予几种研究疗法孤儿药称号。在亚太地区，日本等国家日益提高的医疗保健意识和政府支持（《孤儿药法案》鼓励罕见疾病治疗的发展）正在提振市场前景。此外，澳洲一家着名医疗保健提供者推出的远距医疗平台增加了患者接触专家的机会，特别是在农村地区，从而支持更好的疾病管理。

安德森塔维尔症候群治疗市场-竞争格局：

安德森-塔维尔症候群治疗市场的竞争非常激烈，由于大量的研发投资和主要製药公司的存在，北美成为领先地区。 2023 年，一家美国生物技术公司宣布与一家欧洲公司进行策略性合併，以加速钾通道调节剂的开发，这是一种治疗与安德森-塔维尔症候群相关的周期性麻痹的有前景的药物。此外，学术机构和产业领导者之间的合作已经开展了 40 多项针对新型基因疗法的临床试验。欧洲也发挥着至关重要的作用，多家製药公司获得了 EMA 的孤儿药资格认定，增强了该地区的竞争优势。同时，在亚太地区，一家日本公司最近推出了针对罕见遗传疾病的突破性基因治疗平台，增强了其市场地位。这些倡议，加上远距医疗平台在全球范围内的日益普及，凸显了安德森-塔维尔症候群治疗市场的动态和竞争性质。

最新进展：

2021 年 4 月，Karo Pharma Aktiebolag 收购了 Teva Pharmaceuticals，以扩大其欧洲 OTC 产品组合和罕见疾病研究。 Sun Pharmaceutical Industries Ltd. 透过其子公司 ABCD Technologies LLP 收购了 Trikaal Mediinfotech 和 AWACS 66% 的股份。

目录

第 1 章：Andersen Tawil 综合症治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 安德森塔维尔症候群治疗市场片段（依治疗类型）
    • 安德森 Tawil 症候群治疗市场片段（按药物类别）
    • 安德森 Tawil 症候群治疗市场片段（按给药途径）
    • 最终使用者的 Andersen Tawil 症候群治疗市场片段
    • 安德森塔维尔症候群治疗市场片段（按国家/地区）
    • 安德森塔维尔症候群治疗市场片段（按地区）
  • 竞争洞察

第 3 章：Andersen Tawil 症候群治疗主要市场趋势

  • 安德森塔维尔症候群治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 安德森泰维尔症候群治疗市场限制
    • 市场限制影响分析
  • 安德森塔维尔症候群治疗市场机会
  • 安德森塔维尔症候群治疗市场未来趋势

第 4 章：Andersen Tawil 综合症治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：Andersen Tawil 症候群治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：Andersen Tawil 综合症治疗市场格局

  • Andersen Tawil 症候群治疗市占率分析，2023 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：Andersen Tawil 症候群治疗市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 药物
    • 物理治疗

第 8 章：Andersen Tawil 症候群治疗市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 碳酸酐酶抑制剂
    • β-受体阻断剂
    • 钾补充剂

第 9 章：Andersen Tawil 症候群治疗市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 口服
    • 静脉

第 10 章：Andersen Tawil 综合症治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 专科诊所
    • 研究所

第 11 章：Andersen Tawil 综合症治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • Andersen Tawil 综合症治疗北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • Andersen Tawil 综合症治疗欧洲主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • Andersen Tawil 综合症治疗药物亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • Andersen Tawil 症候群治疗拉丁美洲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • Andersen Tawil 症候群治疗药物中东和非洲主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按治疗类型）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - Andersen Tawil 综合症治疗产业

  • 竞争仪表板
  • 公司简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4287

REPORT HIGHLIGHT

Andersen Tawil Syndrome Treatment Market size was valued at USD 1,765.23 Million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

The Andersen-Tawil Syndrome Treatment Market focuses on therapeutic solutions for a rare genetic disorder characterized by periodic paralysis, cardiac arrhythmias, and distinctive physical features. Growing advancements in genetic research and precision medicine have fueled the development of targeted therapies, enhancing patient outcomes. Increasing awareness among healthcare professionals and improved diagnostic capabilities have contributed to the early detection of the syndrome, with nearly 70% of cases now identified through genetic testing. However, the high cost of treatment and limited availability of specialized healthcare facilities pose significant challenges. Market opportunities include the development of novel therapies and the expansion of telemedicine services to support remote patient management.

Andersen Tawil Syndrome Treatment Market- Market Dynamics

Advancements in Genetic Therapies and Telemedicine Expansion Propel Growth in the Andersen-Tawil Syndrome Treatment Market

Advancements in genetic therapies, coupled with the expansion of telemedicine services, are significantly boosting the Andersen-Tawil Syndrome Treatment Market. The implementation of telehealth platforms, supported by initiatives such as the U.S. Telehealth Modernization Act, has increased access to specialized care for patients in remote areas. Institutions like the National Institutes of Health (NIH) are funding research to develop targeted therapies, with over 50 active studies focusing on genetic disorders, including Andersen-Tawil Syndrome. Moreover, the growing integration of telemedicine into healthcare systems has allowed nearly 60% of rare disease patients to consult specialists without the need for travel, improving management and adherence to treatment protocols.

Andersen Tawil Syndrome Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Medication was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Carbonic anhydrase inhibitors were the leading type in 2023

Based on Route of Administration segmentation, Oral administration was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Andersen Tawil Syndrome Treatment Market- Segmentation Analysis:

The Global Andersen Tawil Syndrome Treatment Market is segmented based on Treatment Type, Drug Class, Route of Administration, End-User, and Region.

The market is divided into two categories based on Treatment Type: Medication and Physical Therapy. Medication holds the highest priority in the Andersen-Tawil Syndrome Treatment Market, as it directly addresses symptoms like cardiac arrhythmias and periodic paralysis. Physical therapy follows, playing a vital role in improving muscle strength and mobility for long-term management and patient quality of life.

The market is divided into three categories based on Drug Class: Carbonic Anhydrase Inhibitors, Beta-Blockers, and Potassium Supplements. Carbonic anhydrase inhibitors are prioritized for their effectiveness in managing periodic paralysis episodes. Beta-blockers follow, addressing cardiac arrhythmias commonly seen in Andersen-Tawil Syndrome. Potassium supplements hold third priority, essential for correcting hypokalemia and stabilizing muscle and cardiac function in patients.

Andersen Tawil Syndrome Treatment Market- Geographical Insights

North America dominates the Andersen-Tawil Syndrome Treatment Market, driven by robust healthcare infrastructure and increased funding for rare disease research. The region benefits from initiatives like the Rare Disease Clinical Research Network (RDCRN), supported by the National Institutes of Health (NIH), which has facilitated over 70 collaborative studies on genetic disorders. The U.S. also witnessed a key partnership in 2023 between a leading pharmaceutical company and a biotech firm to develop novel potassium channel modulators aimed at addressing periodic paralysis associated with Andersen-Tawil Syndrome. Europe follows closely, with the European Medicines Agency (EMA) granting orphan drug designation to several investigational therapies. In Asia-Pacific, rising healthcare awareness and government support in countries like Japan, where the Orphan Drug Act encourages rare disease treatment development, are boosting market prospects. Furthermore, the launch of a telemedicine platform by a prominent healthcare provider in Australia has increased patient access to specialists, especially in rural regions, supporting better disease management.

Andersen Tawil Syndrome Treatment Market- Competitive Landscape:

The Andersen-Tawil Syndrome Treatment Market is marked by strong competition, with North America emerging as the leading region due to significant R&D investments and the presence of major pharmaceutical players. In 2023, a U.S.-based biotech company announced a strategic merger with a European firm to accelerate the development of potassium channel modulators, a promising treatment for periodic paralysis linked to Andersen-Tawil Syndrome. Additionally, collaborations between academic institutions and industry leaders have resulted in over 40 clinical trials focused on novel genetic therapies. Europe also plays a crucial role, with several pharmaceutical companies receiving orphan drug designations from the EMA, boosting the region's competitive edge. Meanwhile, in the Asia-Pacific, a Japanese firm recently launched a groundbreaking gene therapy platform targeting rare genetic disorders, enhancing its market position. These initiatives, coupled with the increasing adoption of telemedicine platforms globally, underscore the dynamic and competitive nature of the Andersen-Tawil Syndrome Treatment Market.

Recent Developments:

In April 2021, Karo Pharma Aktiebolag acquired Teva Pharmaceuticals to expand its European OTC portfolio and rare disease research. Sun Pharmaceutical Industries Ltd. acquired a 66% stake in Trikaal Mediinfotech and AWACS through its subsidiary, ABCD Technologies LLP.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Physical Therapy

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Carbonic Anhydrase Inhibitors
  • Beta-Blockers
  • Potassium Supplements

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Research Institutes

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Andersen Tawil Syndrome Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Andersen Tawil Syndrome Treatment Market Snippet by Treatment Type
    • 2.1.2. Andersen Tawil Syndrome Treatment Market Snippet by Drug Class
    • 2.1.3. Andersen Tawil Syndrome Treatment Market Snippet by Route of Administration
    • 2.1.4. Andersen Tawil Syndrome Treatment Market Snippet by End-User
    • 2.1.5. Andersen Tawil Syndrome Treatment Market Snippet by Country
    • 2.1.6. Andersen Tawil Syndrome Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Andersen Tawil Syndrome Treatment Key Market Trends

  • 3.1. Andersen Tawil Syndrome Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Andersen Tawil Syndrome Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Andersen Tawil Syndrome Treatment Market Opportunities
  • 3.4. Andersen Tawil Syndrome Treatment Market Future Trends

4. Andersen Tawil Syndrome Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Andersen Tawil Syndrome Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Andersen Tawil Syndrome Treatment Market Landscape

  • 6.1. Andersen Tawil Syndrome Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Andersen Tawil Syndrome Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 7.1.2. Medication
    • 7.1.3. Physical Therapy

8. Andersen Tawil Syndrome Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Carbonic Anhydrase Inhibitors
    • 8.1.3. Beta-Blockers
    • 8.1.4. Potassium Supplements

9. Andersen Tawil Syndrome Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Andersen Tawil Syndrome Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Research Institutes

11. Andersen Tawil Syndrome Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Andersen Tawil Syndrome Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Andersen Tawil Syndrome Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Eisai Co., Ltd.
    • 12.2.7. F. Hoffmann-La Roche AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson Services, Inc.
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Mylan N.V.
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us